OMEROS CORP

For the period ended Dec 31, 2025. Filed Mar 31, 2026.

About this filing

A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.

FY2025 · Filed Mar 31, 2026

OMER$17.30-1.4%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Consolidated Statements of Operations and Comprehensive Loss

(In thousands, except share and per share data)

	Year Ended December 31,
	2025	2024	2023
Costs and expenses:
Research and development	$81,296	$119,523	$114,870
Selling, general and administrative	41,500	47,430	49,660
Total costs and expenses	122,796	166,953	164,530
Loss from operations	(122,796)	(166,953)	(164,530)
Gain on sale of zaltenibart	237,594	—	—
Gain on early extinguishment of term debt, net	17,035	—	—
Gain (loss) on early extinguishment of 2026 Notes	(2,968)	—	4,112
Interest and other income	4,096	11,285	16,342
Interest expense, net of remeasurement adjustments and other	960	(24,675)	(30,844)
Gain (loss) on change in fair value of financial instruments, net	(136,717)	19	—
Loss from continuing operations before income tax expense	(2,796)	(180,324)	(174,920)
Income tax expense	(2,012)	(2,305)	—
Net loss from continuing operations, net of tax	(4,808)	(182,629)	(174,920)
Net income from discontinued operations, net of tax	1,458	25,814	57,107
Net loss	$(3,350)	$(156,815)	$(117,813)
Basic and diluted net income (loss) per share:
Net loss from continuing operations	$(0.08)	$(3.14)	$(2.79)
Net income from discontinued operations	0.03	0.44	0.91
Net loss	$(0.05)	$(2.70)	$(1.88)
Weighted-average shares used to compute basic and diluted net income (loss) per share	63,510,201	58,170,931	62,739,227

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.